JP2021529169A5 - - Google Patents
Info
- Publication number
- JP2021529169A5 JP2021529169A5 JP2020570726A JP2020570726A JP2021529169A5 JP 2021529169 A5 JP2021529169 A5 JP 2021529169A5 JP 2020570726 A JP2020570726 A JP 2020570726A JP 2020570726 A JP2020570726 A JP 2020570726A JP 2021529169 A5 JP2021529169 A5 JP 2021529169A5
- Authority
- JP
- Japan
- Prior art keywords
- therapeutic composition
- composition according
- rest
- inhibitor
- subject
- Prior art date
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024043444A JP2024075673A (ja) | 2018-06-18 | 2024-03-19 | 統合失調症及び他の神経精神障害の治療方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862686346P | 2018-06-18 | 2018-06-18 | |
| US62/686,346 | 2018-06-18 | ||
| PCT/US2019/037754 WO2019246112A1 (en) | 2018-06-18 | 2019-06-18 | Methods of treating schizophrenia and other neuropsychiatric disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024043444A Division JP2024075673A (ja) | 2018-06-18 | 2024-03-19 | 統合失調症及び他の神経精神障害の治療方法 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021529169A JP2021529169A (ja) | 2021-10-28 |
| JPWO2019246112A5 JPWO2019246112A5 (https=) | 2022-05-19 |
| JP2021529169A5 true JP2021529169A5 (https=) | 2022-05-19 |
| JP7555542B2 JP7555542B2 (ja) | 2024-09-25 |
Family
ID=67297259
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020570726A Active JP7555542B2 (ja) | 2018-06-18 | 2019-06-18 | 統合失調症及び他の神経精神障害の治療方法 |
| JP2024043444A Pending JP2024075673A (ja) | 2018-06-18 | 2024-03-19 | 統合失調症及び他の神経精神障害の治療方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024043444A Pending JP2024075673A (ja) | 2018-06-18 | 2024-03-19 | 統合失調症及び他の神経精神障害の治療方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20210260002A1 (https=) |
| EP (1) | EP3806861A1 (https=) |
| JP (2) | JP7555542B2 (https=) |
| KR (1) | KR102847197B1 (https=) |
| CN (1) | CN112566640A (https=) |
| CA (1) | CA3103663A1 (https=) |
| WO (1) | WO2019246112A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20110011658A (ko) | 2008-05-08 | 2011-02-08 | 유니버시티 오브 로체스터 | 최적화된 세포 제제에 의한 수초 질환의 치료 |
| EP2954046B1 (en) | 2013-02-06 | 2025-10-15 | University Of Rochester | Induced pluripotent cell-derived oligodendrocyte progenitor cells for the treatment of myelin disorders |
| US9724432B2 (en) | 2015-04-30 | 2017-08-08 | University Of Rochester | Non-human mammal model of human degenerative disorder, uses thereof, and method of treating human degenerative disorder |
| JP7457505B2 (ja) | 2017-05-10 | 2024-03-28 | ユニバーシティー オブ ロチェスター | 神経精神障害を処置する方法 |
| WO2019246262A2 (en) | 2018-06-21 | 2019-12-26 | University Of Rochester | Methods of treating or inhibiting onset of huntington's disease |
| CN120754249A (zh) * | 2021-09-30 | 2025-10-10 | 上海鲸奇生物科技有限公司 | 直接转分化治疗神经系统疾病 |
| WO2024181416A1 (ja) * | 2023-02-28 | 2024-09-06 | 国立大学法人大阪大学 | オリゴヌクレオチド、ならびにそれを用いるｒｅｓｔ発現抑制剤および医薬組成物 |
| WO2025184089A1 (en) * | 2024-02-29 | 2025-09-04 | Board Of Regents, The University Of Texas System | Compositions and methods of use thereof |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5935811A (en) | 1995-03-03 | 1999-08-10 | California Institute Of Technology | Neuron-restrictive silencer factor nucleic acids |
| JP3756313B2 (ja) | 1997-03-07 | 2006-03-15 | 武 今西 | 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体 |
| US6794499B2 (en) | 1997-09-12 | 2004-09-21 | Exiqon A/S | Oligonucleotide analogues |
| US6838283B2 (en) | 1998-09-29 | 2005-01-04 | Isis Pharmaceuticals Inc. | Antisense modulation of survivin expression |
| CZ296576B6 (cs) | 1999-02-12 | 2006-04-12 | Sankyo Company Limited | Nukleosidový analog a oligonukleotidový analog a farmaceutický prostredek, sonda a primer s jeho obsahem |
| US7098192B2 (en) | 1999-04-08 | 2006-08-29 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of STAT3 expression |
| US7179796B2 (en) | 2000-01-18 | 2007-02-20 | Isis Pharmaceuticals, Inc. | Antisense modulation of PTP1B expression |
| WO2003070918A2 (en) | 2002-02-20 | 2003-08-28 | Ribozyme Pharmaceuticals, Incorporated | Rna interference by modified short interfering nucleic acid |
| US20030027153A1 (en) * | 2001-01-09 | 2003-02-06 | Meyer Joanne M. | Methods and compositions for diagnosing and treating neuropsychiatric disorders such as schizophrenia |
| JP2005504020A (ja) | 2001-07-03 | 2005-02-10 | アイシス・ファーマシューティカルス・インコーポレーテッド | ヌクレアーゼ耐性キメラオリゴヌクレオチド |
| AU2003260370B2 (en) | 2002-08-05 | 2008-05-22 | Silence Therapeutics Gmbh | Further novel forms of interfering RNA molecules |
| EP1393776A1 (en) * | 2002-08-14 | 2004-03-03 | Erasmus University Medical Center Rotterdam | Use of genes identified to be involved in tumor development for the development of anti-cancer drugs and diagnosis of cancer |
| KR100750788B1 (ko) | 2003-09-18 | 2007-08-20 | 아이시스 파마수티컬즈 인코포레이티드 | ｅＩＦ4Ｅ 발현의 조정 |
| AU2005252663B2 (en) | 2004-06-03 | 2011-07-07 | Isis Pharmaceuticals, Inc. | Double strand compositions comprising differentially modified strands for use in gene modulation |
| JP4428296B2 (ja) | 2005-06-10 | 2010-03-10 | セイコーエプソン株式会社 | 表示パネルモジュールおよび表示装置 |
| BRPI0619794B8 (pt) | 2005-12-13 | 2022-06-14 | Univ Kyoto | Uso de um fator de reprogramação, agente para a preparação de uma célula-tronco pluripotente induzida a partir de uma célula somática e métodos para preparar uma célula- tronco pluripotente induzida método e para preparar uma célula somática e uso de células-tronco pluripotentes induzidas |
| DK3399025T3 (da) | 2007-03-23 | 2025-06-16 | Wisconsin Alumni Res Found | Omprogrammering af somatiske celler |
| JP2008307007A (ja) | 2007-06-15 | 2008-12-25 | Bayer Schering Pharma Ag | 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞 |
| WO2009027349A2 (en) | 2007-08-24 | 2009-03-05 | Oryzon Genomics Sa | Treatment and prevention of neurodegenerative diseases |
| US10047346B2 (en) | 2008-08-08 | 2018-08-14 | Mayo Foundation For Medical Education And Research | Method of treating heart tissue using induced pluripotent stem cells |
| WO2011031998A1 (en) * | 2009-09-11 | 2011-03-17 | Isis Pharmaceuticals, Inc. | Modulation of re1 silencing transcription factor expression |
| US20120276070A1 (en) | 2009-11-17 | 2012-11-01 | Vitro Diagnositics, Inc. | Induced Pluripotent Stem Cells and Related Methods |
| US9005967B2 (en) | 2010-01-22 | 2015-04-14 | Kyoto University | Myc variants improve induced pluripotent stem cell generation efficiency |
| KR101235256B1 (ko) * | 2010-09-13 | 2013-02-21 | 서울대학교산학협력단 | ｍｉＲＮＡ를 타겟으로 한 신경퇴행성 질환 치료 |
-
2019
- 2019-06-18 CN CN201980053363.2A patent/CN112566640A/zh active Pending
- 2019-06-18 US US17/254,008 patent/US20210260002A1/en active Pending
- 2019-06-18 WO PCT/US2019/037754 patent/WO2019246112A1/en not_active Ceased
- 2019-06-18 KR KR1020217001589A patent/KR102847197B1/ko active Active
- 2019-06-18 EP EP19740110.2A patent/EP3806861A1/en active Pending
- 2019-06-18 JP JP2020570726A patent/JP7555542B2/ja active Active
- 2019-06-18 CA CA3103663A patent/CA3103663A1/en active Pending
-
2024
- 2024-03-19 JP JP2024043444A patent/JP2024075673A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021529169A5 (https=) | ||
| Lau et al. | An aging, pathology burden, and glial senescence build-up hypothesis for late onset Alzheimer’s disease | |
| Wu et al. | Functional roles and networks of non-coding RNAs in the pathogenesis of neurodegenerative diseases | |
| Matos et al. | Machado–Joseph disease/spinocerebellar ataxia type 3: lessons from disease pathogenesis and clues into therapy | |
| Lee et al. | miR‐206 regulates brain‐derived neurotrophic factor in Alzheimer disease model | |
| JP2025172101A (ja) | ドライアイの治療用医薬組成物 | |
| CN103189069B (zh) | 以miRNA为靶的神经退行性疾病的治疗 | |
| Qin et al. | Cross-talk between KLF4 and STAT3 regulates axon regeneration | |
| US11221329B2 (en) | Treatment of neurological and neurodevelopmental diseases and disorders associated with aberrant ion channel expression and activity | |
| Hennig et al. | Transcription coactivators p300 and CBP are necessary for photoreceptor-specific chromatin organization and gene expression | |
| US10801027B2 (en) | Inhibitors of SRSF1 to treat neurodegenerative disorders | |
| US12157889B2 (en) | Methods to detect motor neuron disease comprising micro-RNAs | |
| JP2022515881A (ja) | オリゴ核酸分子及びその応用 | |
| JPWO2019246112A5 (https=) | ||
| Fang et al. | Silencing miR-155–5p alleviates hippocampal damage in kainic acid-induced epileptic rats via the Dusp14/MAPK pathway | |
| US20200071699A1 (en) | Treatment of alzheimers disease with micro rna and ghrelin | |
| Gomaa et al. | Prasugrel anti-ischemic effect in rats: modulation of hippocampal SUMO2/3-IкBα/Ubc9 and SIRT-1/miR-22 trajectories | |
| JPWO2020123663A5 (https=) | ||
| KR20250109188A (ko) | 알츠하이머병 및 기타 뇌 질환을 치료하는 조성물 및 방법 | |
| Yuan et al. | Upregulation of miR-424 inhibit retinal endothelial cells proliferation under high glucose condition via cyclin D1. | |
| KR102360028B1 (ko) | Smurf2의 저해제를 포함하는 세포 또는 개체의 노화를 감소시키기 위한 조성물 및 그의 용도 | |
| Bayram et al. | Decreased hdac1 gene expression in patients with alzheimer’s disease | |
| CN112779252B (zh) | 靶向SMN2启动子区MeCP2结合的关键甲基化区域的反义寡核苷酸 | |
| Orenay-Boyacioglu et al. | Alzheimer’s Disease and Epigenetics | |
| Schroeder et al. | Genetic and pharmacological reversibility of phenotypes in mouse models of autism spectrum disorder |